154 results on '"Pochesci, A."'
Search Results
2. Inter-hospital cardiorespiratory telemonitoring of newborns and infants: a wellworking example of a hub and spoke network
- Author
-
Cinzia Arzilli, Monica Annunziata, Carola-Maria Ernst, Marta Peruzzi, Chiara Macucci, Saverio Pochesci, and Niccolò Nassi
- Subjects
Telemedicine network ,Hub-and-spoke system ,Apnoea of prematurity ,Apparent life-threatening events ,Pediatrics ,RJ1-570 - Abstract
Abstract Background Patients who experience cardiorespiratory events usually have to be moved to specialized centers to perform cardiorespiratory studies. To avoid the transfer of these patients to specialized centers, a network has been created based on an interchange system, where the recordings were uploaded in unspecialized centers (spokes) and downloaded by the Sleep Disorders Breathing (SDB) Center (hub) to be analyzed. Methods The inter-hospital network was established in November 2008. Initially only 3 non-tertiary hospitals in the Tuscany Region joined the network. Currently, 12 Tuscany hospitals are included. Results From November 2008 to December 2020, 625 recordings were collected belonging to 422 infants. No recurrent life-threatening episode or infant death occurred in the study population and none of the infants needed to be readmitted or be moved to a tertiary center, except infants who underwent home monitoring. The discharge diagnoses belong to the following categories: apnoea, respiratory problem of the newborn, syncope, gastroesophageal reflux, altered consciousness, transient loss of consciousness and cyanosis. Conclusions This study shows that the inter-hospital network is an efficient system that allows accurate and safe management of infants at risk for apnoea, bradycardia, and hypoxemia to remain in unspecialized centers, avoiding unnecessary transfers of patients and over – hospitalizations.
- Published
- 2023
- Full Text
- View/download PDF
3. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
- Author
-
Peters, Solange, Danson, Sarah, Ejedepang, Dunson, Dafni, Urania, Hasan, Baktiar, Radcliffe, Hoi-Shen, Bustin, Frederique, Crequit, Jacky, Coate, Linda, Guillot, Monica, Surmont, Veerle, Rauch, Daniel, Rudzki, Jakob, O'Mahony, Deirdre, Barneto Aranda, Isidoro, Scherz, Amina, Tsourti, Zoi, Roschitzki-Voser, Heidi, Pochesci, Alessia, Demonty, Gaston, Stahel, Rolf A., and O'Brien, Mary
- Published
- 2021
- Full Text
- View/download PDF
4. P919 Crohn’s Disease Exclusion Diet as add-on therapy in refractory pediatric patients
- Author
-
Scarallo, L, primary, Pochesci, S, additional, Fioretti, L, additional, Paci, M, additional, Renzo, S, additional, Naldini, S, additional, Lacitignola, L, additional, Barp, J, additional, Banci, E, additional, De Blasi, A, additional, and Lionetti, P, additional
- Published
- 2024
- Full Text
- View/download PDF
5. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
- Author
-
Peters, Solange, Danson, Sarah, Hasan, Baktiar, Dafni, Urania, Reinmuth, Niels, Majem, Margarita, Tournoy, Kurt G., Mark, Michael T., Pless, Miklos, Cobo, Manuel, Rodriguez-Abreu, Delvys, Falchero, Lionel, Moran, Teresa, Ortega Granados, Ana Laura, Monnet, Isabelle, Mohorcic, Katja, Sureda, Bartomeu Massutí, Betticher, Daniel, Demedts, Ingel, Macias, Jose Antionio, Cuffe, Sinead, Luciani, Andrea, Sanchez, Jose Garcia, Curioni-Fontecedro, Alessandra, Gautschi, Oliver, Price, Gillian, Coate, Linda, von Moos, Roger, Zielinski, Christoph, Provencio, Mariano, Menis, Jessica, Ruepp, Barbara, Pochesci, Alessia, Roschitzki-Voser, Heidi, Besse, Benjamin, Rabaglio, Manuela, O’Brien, Mary E.R., and Stahel, Rolf A.
- Published
- 2020
- Full Text
- View/download PDF
6. P680 A real-life experience of Crohn’s Disease Exclusion Diet use at disease onset and as an add-on therapy in pediatric Crohn’s disease
- Author
-
L Scarallo, L Fioretti, S Pochesci, V Pierattini, E Banci, A De Blasi, M Di Paola, and P Lionetti
- Subjects
Gastroenterology ,General Medicine - Abstract
Background We aimed at appraising real-life efficacy of Crohn’s Disease Exclusion Diet (CDED) coupled with partial enteral nutrition (PEN) in inducing clinical and biochemical remission at disease onset and in patients with loss of response to biologics in a tertiary-level center. We also aimed at identifying early responders to this dietary regimen. Methods We gathered clinical, anthropometric and laboratory data of patients aged less then 18 years of age with a diagnosis of CD, who were consecutively treated with CDED coupled with PEN as main treatment for the induction of remission or in the setting of loss of response to other therapies. We collected data of patients who received CDED plus PEN from April 2019 to June 2022 at diagnosis, at the beginning of the dietary treatment, and at the phase 1. Patients who interrupted diet during follow-up were considered as treatment failures on an intent to treat basis. We compared groups using chi-square, Fisher’s exact test, Mann-Whitney U or related-samples Wilcoxon signed rank tests or McNemar’s test as appropriate. Results 47 patients were retrospectively identified. Table 1. summarizes clinical and biochemical characteristics at diagnosis and at CDED with PEN initiation. 24 (51.1%) patients started CDED as induction therapy at disease onset, whereas 23 (48.9%) of them received CDED with PEN as add-on therapy. 32/47 (68%) patients achieved clinical remission (wPCDAI < 12.5) at the end of phase 1, 16/24 patients (66.7%) who started CDED as induction therapy and 16/23 (69.5%) of those who started CDED as add-on, with no statistically significant difference among the two groups (p=1.00). Laboratory parameters significantly improved in both groups (Figure 1.). There were no statistically significant differences in clinical remission rates between patients with mild-to-moderate and severe disease at the end of phase 1 (25/35 vs 7/12, p=0.481). At disease onset, 14 patients added a concomitant treatment (11 patients added anti-TNF alpha, 3 patients added IMM and one patient added anti-TNF alpha + IMM) after a median time of 4 weeks (IQR: 3-5 weeks). 28 patients had clinical data gathered at week 3. Patients who achieved clinical response at week 3 (a change in wPCDAI > 12.5) were more likely to be in clinical remission at the end of phase 1 (17/20 vs 1/8, p Conclusion CDED with PEN confirmed its efficacy in a real-life setting, both as induction regimen and as add-on therapy, also in patients with clinically severe disease. Early clinical response predicts clinical remission at the end of phase 1, possibly allowing identification of dietary responsive disease. Table 1. Figure 1.
- Published
- 2023
7. P680 A real-life experience of Crohn’s Disease Exclusion Diet use at disease onset and as an add-on therapy in pediatric Crohn’s disease
- Author
-
Scarallo, L, primary, Fioretti, L, additional, Pochesci, S, additional, Pierattini, V, additional, Banci, E, additional, De Blasi, A, additional, Di Paola, M, additional, and Lionetti, P, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
- Author
-
Passaro A, Lazzari C, Karachaliou N, Spitaleri G, Pochesci A, Catania C, Rosell R, and de Marinis F
- Subjects
ALK ,NSCLC ,crizotinib ,ceritinib ,alectinib ,brigatinib ,lorlatinib ,brain metastases ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Antonio Passaro,1 Chiara Lazzari,1,2 Niki Karachaliou,3 Gianluca Spitaleri,1 Alessia Pochesci,1 Chiara Catania,1 Rafael Rosell,4 Filippo de Marinis1 1Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy; 2Department of Medical Oncology, Division of Experimental Medicine, San Raffaele Scientific Institute, Milan, Italy; 3Oncology Institute Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain; 4Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain Abstract: The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second- or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naïve ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed. Keywords: ALK, NSCLC, crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, brain metastases
- Published
- 2016
9. Fabrication and test of RF MEMS in LTCC technology
- Author
-
Lucibello, Andrea, Marcelli, Romolo, Di Paola, Ernesto, Di Nardo, Sergio, Pochesci, Daniele, Croci, Renato, and Germani, Chiara
- Published
- 2017
- Full Text
- View/download PDF
10. Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer
- Author
-
Rampinelli, Cristiano, Spitaleri, Gianluca, Passaro, Antonio, Pochesci, Alessia, Ancona, Eleonora, and De Marinis, Filippo
- Published
- 2017
- Full Text
- View/download PDF
11. Inter-hospital cardiorespiratory telemonitoring of newborns and infants
- Author
-
Cinzia Arzilli, Monica Annunziata, Carola Maria Ernst, Marta Peruzzi, Chiara Macucci, Saverio Pochesci, and Niccolò Nassi
- Abstract
Cardiorespiratory monitoring is recommended for the assessment of symptomatic preterm newborns and infants with a clinical history of Apparent Life-Threatening Events (ALTE). Patients who experience cardiorespiratory events usually have to be moved to specialized centers to perform cardiorespiratory studies. To avoid the transfer of these patients to specialized centers, it has been created a network based on an interchange system where the recordings were uploaded in unspecialized centers (spokes) and downloaded by the Sleep Disorders Breathing (SDB) Center (hub) to be analyzed. From November 2008 to December 2020 cardiorespiratory recordings belonging to 422 patients were collected. This study shows that the inter-hospital network is an efficient system that allows accurate and safe management of infants at risk of apnoea, bradycardia, and hypoxemia also in unspecialized centers, avoiding unnecessary transfers of patients and over – hospitalizations.
- Published
- 2022
12. Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
- Author
-
Passaro, Antonio, Guerini-Rocco, Elena, Pochesci, Alessia, Vacirca, Davide, Spitaleri, Gianluca, Catania, Chiara Matilde, Rappa, Alessandra, Barberis, Massimo, and de Marinis, Filippo
- Published
- 2017
- Full Text
- View/download PDF
13. Design of RF MEMS based switch matrix for space applications
- Author
-
S. Di Nardo, P. Farinelli, T. Kim, R. Marcelli, B. Margesin, E. Paola, D. Pochesci, L. Vietzorreck, and F. Vitulli
- Subjects
Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
RF MEMS based switch matrices have several advantages compared to the mechanical or solid-state switch based ones for space applications. They are compact, light and less lossy with a high linearity up to high frequency. In this work, a 12 × 12 switch matrix with RF MEMS and LTCC technologies is presented based on the planar Beneš network. The simulated performance of the 12 × 12 switch matrix is below −12 dB IL (Insertion Loss) up to C band and −15 dB RL (Return Loss) up to Ku band. Moreover, it has a good isolation better than −50 dB. A 4 × 4 switch matrix with the same design process and technologies is fabricated and measured to verify the 12 × 12 switch matrix design process. The measured performance agrees very well to the simulations.
- Published
- 2013
- Full Text
- View/download PDF
14. Inter-hospital cardiorespiratory telemonitoring of newborns and infants.
- Author
-
Arzilli, Cinzia, primary, Annunziata, Monica, additional, Ernst, Carola Maria, additional, Peruzzi, Marta, additional, Macucci, Chiara, additional, Pochesci, Saverio, additional, and Nassi, Niccolò, additional
- Published
- 2022
- Full Text
- View/download PDF
15. LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial
- Author
-
Girard, N., primary, Ponce Aix, S., additional, Cedres, S., additional, Berghmans, T., additional, Burgers, S., additional, Toffart, A.C., additional, Popat, S., additional, Janssens, A., additional, Gervais, R., additional, Hochstenbag, M., additional, Silva, M., additional, Burger, I., additional, Prosch, H., additional, Stahel, R.A., additional, Govaerts, A-S., additional, Pochesci, A., additional, Neven, A., additional, and Peters, S., additional
- Published
- 2021
- Full Text
- View/download PDF
16. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
- Author
-
Linda Coate, Zoi Tsourti, Gaston Demonty, Frederique Bustin, Daniel Rauch, H. Roschitzki-Voser, A. Pochesci, Veerle Surmont, M Guillot, Jakob Rudzki, Dunson Ejedepang, Isidoro Barneto Aranda, Baktiar Hasan, Rolf A. Stahel, Urania Dafni, Mary O'Brien, Hoi-Shen Radcliffe, Amina Scherz, Jacky Crequit, Deirdre O'Mahony, Sarah Danson, and Solange Peters
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Population ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Clinical endpoint ,Humans ,education ,Chemotherapy ,education.field_of_study ,business.industry ,Proportional hazards model ,Bone metastasis ,medicine.disease ,Progression-Free Survival ,Denosumab ,Pooled analysis ,First line chemotherapy ,business ,610 Medizin und Gesundheit ,medicine.drug - Abstract
Introduction\ud \ud The efficacy of adding denosumab to standard first-line chemotherapy for advanced NSCLC patients has been evaluated in two separate randomised trials (SPLENDOUR and AMGEN-249). In this pooled analysis, we will assess the combination-treatment effect in the largest available population, in order to conclude about the potential impact of denosumab in NSCLC.\ud \ud \ud \ud Methods\ud \ud Both trials included in this combined analysis, were randomised (SPLENDOUR 1:1, AMGEN-249 2:1) multi-centre trials stratified by histology, bone metastasis, geographical region and for SPLENDOUR only, ECOG PS. Cox proportional hazards models, were used to assess the treatment effect with respect to overall survival (OS; primary endpoint) and progression-free survival (PFS; secondary endpoint). Heterogeneity between trials was assessed, and subgroup analyses were performed.\ud \ud \ud \ud Results\ud \ud The pooled analysis was based on 740 randomised patients (SPLENDOUR:514; AMGEN-249:226), with 407 patients in the chemotherapy-denosumab arm and 333 in the chemotherapy-alone arm.\ud \ud \ud \ud In the chemotherapy-denosumab arm, at a median follow-up of 22.0 months, 277 (68.1%) deaths were reported with median OS 9.2 months (95%CI:[8.0–10.7]), while in the chemotherapy-alone arm, with similar median follow-up of 20.3 months, 230 (69.1%) deaths with median OS 9.9 months (95%CI:[8.2–11.2]). No significant denosumab effect was found (HR = 0.98; 95%CI:[0.82–1.18]; P = 0.85).\ud \ud \ud \ud Among subgroups, interaction was found between treatment and histology subtypes (P = 0.020), with a statistically significant benefit in the squamous group (HR = 0.70; 95%CI:[0.49–0.98]; P = 0.038), from 7.6 to 9.0 months median OS.\ud \ud \ud \ud With respect to PFS, 363 (89.2%) and 298 (89.5%) events were reported in the chemotherapy-denosumab and chemotherapy-alone arms, respectively, with corresponding medians 4.8 months (95%CI:[4.4–5.3]) and 4.9 months (95%CI:[4.3–5.4]). HR for PFS was 0.97 (95%CI:[0.83–1.15]; P = 0.76), indicating that no significant denosumab benefit existed for PFS.\ud \ud \ud \ud Conclusion\ud \ud In this pooled analysis, no statistically significant improvement was shown in PFS/OS with the combination of denosumab and chemotherapy for advanced NSCLC and no meaningful benefit in any of the subgroups.
- Published
- 2021
17. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
- Author
-
Peters, Solange Danson, Sarah Ejedepang, Dunson Dafni, Urania Hasan, Baktiar Radcliffe, Hoi-Shen Bustin, Frederique and Crequit, Jacky Coate, Linda Guillot, Monica Surmont, Veerle Rauch, Daniel Rudzki, Jakob O'Mahony, Deirdre and Aranda, Isidoro Barneto Scherz, Amina Tsourti, Zoi and Roschitzki-Voser, Heidi Pochesci, Alessia Demonty, Gaston and Stahel, Rolf A. O'Brien, Mary
- Abstract
Introduction: The efficacy of adding denosumab to standard first-line chemotherapy for advanced NSCLC patients has been evaluated in two separate randomised trials (SPLENDOUR and AMGEN-249). In this pooled analysis, we will assess the combination-treatment effect in the largest available population, in order to conclude about the potential impact of denosumab in NSCLC. Methods: Both trials included in this combined analysis, were randomised (SPLENDOUR 1:1, AMGEN-249 2:1) multi-centre trials stratified by histology, bone metastasis, geographical region and for SPLENDOUR only, ECOG PS. Cox proportional hazards models, were used to assess the treatment effect with respect to overall survival (OS; primary endpoint) and progression-free survival (PFS; secondary endpoint). Heterogeneity between trials was assessed, and subgroup analyses were performed. Results: The pooled analysis was based on 740 randomised patients (SPLENDOUR:514; AMGEN-249:226), with 407 patients in the chemotherapy-denosumab arm and 333 in the chemotherapy-alone arm. In the chemotherapy-denosumab arm, at a median follow-up of 22.0 months, 277 (68.1%) deaths were reported with median OS 9.2 months (95%CI:[8.0-10.7]), while in the chemotherapy-alone arm, with similar median follow-up of 20.3 months, 230 (69.1%) deaths with median OS 9.9 months (95%CI:[8.2-11.2]). No significant denosumab effect was found (HR = 0.98; 95%CI:[0.82-1.18]; P = 0.85). Among subgroups, interaction was found between treatment and histology subtypes (P = 0.020), with a sta-tistically significant benefit in the squamous group (HR = 0.70; 95%CI:[0.49-0.98]; P = 0.038), from 7.6 to 9.0 months median OS. With respect to PFS, 363 (89.2%) and 298 (89.5%) events were reported in the chemotherapy-denosumab and chemotherapy-alone arms, respectively, with corresponding medians 4.8 months (95%CI:[4.4-5.3]) and 4.9 months (95%CI:[4.3-5.4]). HR for PFS was 0.97 (95%CI:[0.83-1.15]; P = 0.76), indicating that no significant denosumab benefit existed for PFS. Conclusion: In this pooled analysis, no statistically significant improvement was shown in PFS/OS with the combination of denosumab and chemotherapy for advanced NSCLC and no meaningful benefit in any of the subgroups.
- Published
- 2021
18. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy
- Author
-
Samantha C. Sodergren, Galina Velikova, Jammbe Z. Musoro, A. Pochesci, Corneel Coens, Mitsumi Terada, M. A. G. Sprangers, Madeleine King, Kim Cocks, Mogens Groenvold, Andrew Bottomley, Henning Flechtner, Medical Psychology, APH - Mental Health, APH - Personalized Medicine, CCA - Cancer Treatment and Quality of Life, and APH - Aging & Later Life
- Subjects
Oncology ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,clinical anchors ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Surveys and Questionnaires ,Internal medicine ,otorhinolaryngologic diseases ,medicine ,Humans ,health-related quality of life (HRQOL) ,Clinical significance ,In patient ,Advanced colorectal cancer ,Chemotherapy ,business.industry ,Gastroenterology ,Cancer ,EORTC QLQ-C30 ,social sciences ,medicine.disease ,humanities ,Clinical trial ,minimally important difference (MID) ,Research Design ,Sample size determination ,030220 oncology & carcinogenesis ,Linear Models ,Quality of Life ,030211 gastroenterology & hepatology ,Colorectal Neoplasms ,business - Abstract
AimThe European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30) assesses the health‐related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ‐C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ‐C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials.MethodThe data were obtained from three published EORTC trials that treated CRC patients using chemotherapy. Potential anchors were selected from clinical variables based on their correlation with EORTC QLQ‐C30 scales. Anchor‐based MIDs for within‐group change and between‐group change were estimated via the mean change method and linear regression, respectively, and summarized using weighted correlation. Distribution‐based MIDs were also examined.ResultsAnchor‐based MIDs were determined for deterioration in 8 of the 14 EORTC QLQ‐C30 scales and in 9 scales for improvement, and varied by scale, direction of change and anchor. MIDs for improvement (deterioration) ranged from 6 to 18 (−11 to −5) points for within‐group change and 5 to 15 (−10 to −4) for between‐group change. Summarized MIDs (in absolute values) per scale mostly ranged from 5 to 10 points.ConclusionsThese findings have clinical relevance for the interpretation of treatment efficacy and the design of clinical trials by informing sample size requirements.
- Published
- 2020
19. REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
- Author
-
Besse, B, Menis, J, Bironzo, P, Gervais, R, Greillier, L, Monnet, I, Livi, L, Young, R, Decroisette, C, Cloarec, N, Robinet, G, Schott, R, Califano, R, De Marinis, F, Banna, Gl, Mauer, M, Pochesci, A, Hasan, B, Berghmans, T, and Dingemans, Amc
- Published
- 2020
20. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
- Author
-
H. Roschitzki-Voser, Gillian Price, Rolf A. Stahel, Sinead Cuffe, Urania Dafni, Sarah Danson, Barbara Ruepp, Linda Coate, Roger von Moos, Mariano Provencio, Oliver Gautschi, Miklos Pless, Katja Mohorcic, Margarita Majem, Delvys Rodriguez-Abreu, Lionel Falchero, Bartomeu Massuti Sureda, Andrea Luciani, Solange Peters, M. Cobo, Jose Garcia Sanchez, Ingel K. Demedts, Alessandra Curioni-Fontecedro, Kurt G. Tournoy, Baktiar Hasan, Michael Mark, A. Pochesci, Manuela Rabaglio, Niels Reinmuth, Christoph C. Zielinski, Mary O'Brien, Daniel Betticher, Ana Laura Ortega Granados, Benjamin Besse, Isabelle Monnet, Jose Antionio Macias, Teresa Moran, and Jessica Menis
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Male ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Population ,NSCLC ,RANK ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Lung cancer ,education ,610 Medicine & health ,Aged ,Retrospective Studies ,education.field_of_study ,Chemotherapy ,business.industry ,Bone metastases ,Hazard ratio ,RANKL ,Bone metastasis ,Retrospective cohort study ,Reference Standards ,medicine.disease ,030104 developmental biology ,Zoledronic acid ,Denosumab ,030220 oncology & carcinogenesis ,Female ,business ,medicine.drug - Abstract
Introduction: Receptor activator of NF-kB ligand stimulates NF-kB-dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid in bone metastatic solid tumors suggested significant overall survival (OS) advantage for patients with lung cancer with denosumab (p = 0.01). The randomized open-label phase III SPLENDOUR trial was designed to evaluate whether the addition of denosumab to standard first-line platinum-based doublet chemotherapy improved OS in advanced NSCLC. Methods: Patients with stage IV NSCLC were randomized in a 1:1 ratio to either chemotherapy with or without denosumab (120 mg every 3-4 wks), stratified by the presence of bone metastases (at diagnosis), Eastern Cooperative Oncology Group performance status, histology, and region. To detect an OS increase from 9 to 11.25 months (hazard ratio [HR] = 0.80), 847 OS events were required. The trial closed prematurely owing to decreasing accrual rate. Results: A total of 514 patients were randomized, with 509 receiving one or more doses of the assigned treatment (chemotherapy: 252, chemotherapy-denosumab: 257). The median age was 66.1 years, 71% were men, and 59% were former smokers. Bone metastases were identified in 275 patients (53%). Median OS (95% confidence interval [CI]) was 8.7 (7.6-11.0) months in the control arm versus 8.2 (7.5-10.4) months in the chemotherapy-denosumab arm (HR = 0.96; 95% CI: 0.78-1.19; one-sided p = 0.36). For patients with bone metastasis, HR was 1.02 (95% CI: 0.77-1.35), whereas for those without, HR was 0.90 (95% CI: 0.66-1.23). Adverse events grade 3 or greater were observed in 40.9%, 5.2%, 8.7% versus 45.5%, 10.9%, 10.5% of patients. Conditional power for OS benefit was less than or equal to 10%. Conclusions: Denosumab was well-tolerated without unexpected safety concerns. There was no OS improvement for denosumab when added to chemotherapy in the intention-to-treat population and the subgroups with and without bone metastases. Our data do not provide evidence of a clinical benefit for denosumab in patients with NSCLC without bone metastases. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
- Published
- 2020
21. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
- Author
-
Peters, S. Danson, S. Hasan, B. Dafni, U. Reinmuth, N. Majem, M. Tournoy, K.G. Mark, M.T. Pless, M. Cobo, M. Rodriguez-Abreu, D. Falchero, L. Moran, T. Ortega Granados, A.L. Monnet, I. Mohorcic, K. Sureda, B.M. Betticher, D. Demedts, I. Macias, J.A. Cuffe, S. Luciani, A. Sanchez, J.G. Curioni-Fontecedro, A. Gautschi, O. Price, G. Coate, L. von Moos, R. Zielinski, C. Provencio, M. Menis, J. Ruepp, B. Pochesci, A. Roschitzki-Voser, H. Besse, B. Rabaglio, M. O'Brien, M.E.R. Stahel, R.A.
- Abstract
Introduction: Receptor activator of NF-kB ligand stimulates NF-kB–dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid in bone metastatic solid tumors suggested significant overall survival (OS) advantage for patients with lung cancer with denosumab (p = 0.01). The randomized open-label phase III SPLENDOUR trial was designed to evaluate whether the addition of denosumab to standard first-line platinum-based doublet chemotherapy improved OS in advanced NSCLC. Methods: Patients with stage IV NSCLC were randomized in a 1:1 ratio to either chemotherapy with or without denosumab (120 mg every 3–4 wks), stratified by the presence of bone metastases (at diagnosis), Eastern Cooperative Oncology Group performance status, histology, and region. To detect an OS increase from 9 to 11.25 months (hazard ratio [HR] = 0.80), 847 OS events were required. The trial closed prematurely owing to decreasing accrual rate. Results: A total of 514 patients were randomized, with 509 receiving one or more doses of the assigned treatment (chemotherapy: 252, chemotherapy-denosumab: 257). The median age was 66.1 years, 71% were men, and 59% were former smokers. Bone metastases were identified in 275 patients (53%). Median OS (95% confidence interval [CI]) was 8.7 (7.6–11.0) months in the control arm versus 8.2 (7.5–10.4) months in the chemotherapy-denosumab arm (HR = 0.96; 95% CI: 0.78–1.19; one-sided p = 0.36). For patients with bone metastasis, HR was 1.02 (95% CI: 0.77–1.35), whereas for those without, HR was 0.90 (95% CI: 0.66–1.23). Adverse events grade 3 or greater were observed in 40.9%, 5.2%, 8.7% versus 45.5%, 10.9%, 10.5% of patients. Conditional power for OS benefit was less than or equal to 10%. Conclusions: Denosumab was well-tolerated without unexpected safety concerns. There was no OS improvement for denosumab when added to chemotherapy in the intention-to-treat population and the subgroups with and without bone metastases. Our data do not provide evidence of a clinical benefit for denosumab in patients with NSCLC without bone metastases. © 2020 International Association for the Study of Lung Cancer
- Published
- 2020
22. Fabrication of RF-MEMS switches on LTCC substrates using PECVD a-Si as sacrificial layer
- Author
-
Cianci, E., Coppa, A., Foglietti, V., Dispenza, M., Buttiglione, R., Fiorello, A.M., Marcelli, R., Catoni, S., and Pochesci, D.
- Published
- 2007
- Full Text
- View/download PDF
23. Microwave Inter-Connections and Switching by means of Carbon Nano-tubes
- Author
-
Daniela Dragoman, Mircea Dragoman, Giancarlo Bartolucci, Daniele Pochesci, Romolo Marcelli, Emanuela Proietti, Andrea Lucibello, and Giorgio De Angelis
- Subjects
Carbon Nanotubes ,Microwaves ,Switching ,Band?Gap Engineering ,Materials of engineering and construction. Mechanics of materials ,TA401-492 ,Technology - Abstract
In this work, carbon nanotube (CNT) based interconnections and switches will be reviewed, discussing the possibility to use nanotubes as potential building blocks for signal routing in microwave networks. In particular, theoretical design of coplanar waveguide (CPW), micro-strip single-pole-single-throw (SPST) and single-pole-double-throw (SPDT) devices has been performed to predict the electrical performances of CNT-based RF switching configurations. Actually, by using the semiconductor-conductor transition obtained by properly biasing the CNTs, an isolation better than 30 dB can be obtained between the ON and OFF states of the switch for very wide bandwidth applications. This happens owing to the shape deformation and consequent change in the band-gap due to the external pressure caused by the electric field. State-of-art for other switching techniques based on CNTs and their use for RF nano-interconnections is also discussed, together with current issues in measurement techniques.
- Published
- 2011
- Full Text
- View/download PDF
24. 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)
- Author
-
Menis, J., primary, Bironzo, P., additional, Radj, G., additional, Greillier, L., additional, Monnet, I., additional, Livi, L., additional, Young, R., additional, Decroisette, C., additional, Cloarec, N., additional, Robinet, G., additional, Schott, R., additional, Califano, R., additional, De Marinis, F., additional, Mauer, M., additional, Pochesci, A., additional, Silva, M., additional, Caramella, C., additional, Dingemans, A-M., additional, Dive, C., additional, and Besse, B., additional
- Published
- 2020
- Full Text
- View/download PDF
25. LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
- Author
-
Besse, B., primary, Menis, J., additional, Bironzo, P., additional, Gervais, R., additional, Greillier, L., additional, Monnet, I., additional, Livi, L., additional, Young, R., additional, Decroisette, C., additional, Cloarec, N., additional, Robinet, G., additional, Schott, R., additional, Califano, R., additional, De Marinis, F., additional, Banna, G.L., additional, Mauer, M., additional, Pochesci, A., additional, Hasan, B., additional, Berghmans, T., additional, and Dingemans, A-M.C., additional
- Published
- 2020
- Full Text
- View/download PDF
26. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
- Author
-
Levy, Antonin, primary, Hendriks, Lizza E.L., additional, Berghmans, Thierry, additional, Faivre-Finn, Corinne, additional, GiajLevra, Matteo, additional, GiajLevra, Niccolò, additional, Hasan, Baktiar, additional, Pochesci, Alessia, additional, Girard, Nicolas, additional, Greillier, Laurent, additional, Lantuéjoul, Sylvie, additional, Edwards, John, additional, O'Brien, Mary, additional, Reck, Martin, additional, Besse, Benjamin, additional, Novello, Silvia, additional, and Dingemans, Anne-Marie C., additional
- Published
- 2019
- Full Text
- View/download PDF
27. MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey
- Author
-
Levra, M. Giaj, primary, Benet, J., additional, Hasan, B., additional, Berghmans, T., additional, Bruni, A., additional, Dingemans, A.M., additional, Levra, N. Giaj, additional, Edwards, J., additional, Faivre-Finn, C., additional, Girard, N., additional, Gobbini, E., additional, Greillier, L., additional, Hendriks, L., additional, Lantuejoul, S., additional, Levy, A., additional, Novello, S., additional, O'Brien, M., additional, Reck, M., additional, Pochesci, A., additional, Menis, J., additional, and Besse, B., additional
- Published
- 2019
- Full Text
- View/download PDF
28. P1.06-06 EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma
- Author
-
Van Meerbeeck, J., primary, Van Schil, P., additional, Surmont, V., additional, Gaafar, R., additional, Cornelissen, R., additional, Hasan, B., additional, Pochesci, A., additional, Maat, A., additional, Baas, P., additional, and Vermassen, F., additional
- Published
- 2019
- Full Text
- View/download PDF
29. Fabrication and test of RF MEMS in LTCC technology
- Author
-
Daniele Pochesci, Renato Croci, Sergio Di Nardo, Chiara Germani, Andrea Lucibello, Ernesto Di Paola, and Romolo Marcelli
- Subjects
010302 applied physics ,Microelectromechanical systems ,Engineering ,Fabrication ,business.industry ,Contact resistance ,Electrical engineering ,02 engineering and technology ,021001 nanoscience & nanotechnology ,Condensed Matter Physics ,01 natural sciences ,Electronic, Optical and Magnetic Materials ,Hardware and Architecture ,visual_art ,0103 physical sciences ,visual_art.visual_art_medium ,Ceramic ,Electrical and Electronic Engineering ,0210 nano-technology ,business ,Ohmic contact - Abstract
RF MEMS in low-temperature co-fired ceramics (LTCC) technology have been designed, manufactured and tested for potential utilization in reconfigurable space sub-systems. Specifically, single-pole-single-throw (SPST) and single-pole-double-throw (SPDT) ohmic switch configurations have been studied for wide-band applications. Advantages coming from the measured RF performances and from the integration of RF MEMS by means of the LTCC technology only, to be used also for packaging, are discussed. Furthermore, preliminary on-wafer DC test on a double-pole-double-throw (DPDT) ohmic switch has been done in order to check both the mechanical response and the quality of the ohmic contact (contact resistance).
- Published
- 2017
30. Tax treatment of retirement plan distributions paid to an estate.
- Author
-
Soled, Jay A., Fiszer, George A., Arnell, Nathan E., Wolf, Dena L., and Pochesci, Anthony
- Subjects
Individual retirement accounts -- Taxation ,Estate tax -- Analysis ,Salary reduction savings plans -- Taxation - Published
- 2010
31. LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
- Author
-
Baktiar Hasan, A-M.C. Dingemans, Radj Gervais, Roland Schott, Jessica Menis, Raffaele Califano, R. Young, F. De Marinis, Chantal Decroisette, N. Cloarec, Laurent Greillier, Isabelle Monnet, A. Pochesci, Paolo Bironzo, Benjamin Besse, Thierry Berghmans, Gilles Robinet, Lorenzo Livi, Murielle Mauer, and Giuseppe Luigi Banna
- Subjects
business.industry ,Phases of clinical research ,Hematology ,Pembrolizumab ,Carboplatin ,chemistry.chemical_compound ,Oncology ,chemistry ,medicine ,Cancer research ,Non small cell ,business ,Etoposide ,medicine.drug - Published
- 2020
32. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
- Author
-
Gianluca Spitaleri, Filippo de Marinis, Niki Karachaliou, Chiara Catania, Antonio Passaro, Chiara Lazzari, Alessia Pochesci, and Rafael Rosell
- Subjects
0301 basic medicine ,Oncology ,Alectinib ,brigatinib ,medicine.medical_specialty ,Brigatinib ,Review ,NSCLC ,03 medical and health sciences ,0302 clinical medicine ,lorlatinib ,brain metastases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,ceritinib ,Anaplastic lymphoma kinase ,alectinib ,Pharmacology (medical) ,Lung cancer ,crizotinib ,Crizotinib ,Ceritinib ,business.industry ,medicine.disease ,Lorlatinib ,respiratory tract diseases ,030104 developmental biology ,ALK ,030220 oncology & carcinogenesis ,business ,Tyrosine kinase ,medicine.drug - Abstract
The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second- or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naïve ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed.
- Published
- 2016
33. MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey
- Author
-
Jessica Menis, Nicolas Girard, Corinne Faivre-Finn, A. Pochesci, M. Giaj Levra, N. Giaj Levra, Laurent Greillier, Thierry Berghmans, A.M. Dingemans, Silvia Novello, Mary O'Brien, Martin Reck, Antonin Levy, Alessio Bruni, Benjamin Besse, Lizza E.L. Hendriks, Sylvie Lantuejoul, Elisa Gobbini, John G. Edwards, J. Benet, and Baktiar Hasan
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Durvalumab ,business.industry ,Internal medicine ,medicine ,Treatment strategy ,Lung cancer ,medicine.disease ,business ,Stage III Non-Small Cell Lung Cancer - Published
- 2019
34. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
- Author
-
Nicolas Girard, Sylvie Lantuejoul, Niccolò Giaj-Levra, Martin Reck, Thierry Berghmans, John G. Edwards, Matteo Giaj-Levra, Antonin Levy, Silvia Novello, Benjamin Besse, Lizza E.L. Hendriks, Mary O'Brien, Laurent Greillier, Anne-Marie C. Dingemans, Baktiar Hasan, Corinne Faivre-Finn, A. Pochesci, Pulmonary Medicine, Pulmonologie, Promovendi ODB, MUMC+: MA Med Staf Spec Longziekten (9), and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Consensus ,THERAPY ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,EUROPEAN ORGANIZATION ,Non-small cell lung cancer ,SDG 3 - Good Health and Well-being ,Carcinoma, Non-Small-Cell Lung ,Thoracic Oncology ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,Lung cancer ,Radiation oncologist ,Aged ,Neoplasm Staging ,Oligometastasis ,medicine.diagnostic_test ,business.industry ,Mediastinum ,Cancer ,STEREOTACTIC BODY RADIOTHERAPY ,Middle Aged ,medicine.disease ,Clinical trial ,030104 developmental biology ,Positron emission tomography ,030220 oncology & carcinogenesis ,Mediastinal lymph node ,PHASE-II ,Female ,TRIAL ,Lymph Nodes ,business - Abstract
Background Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non–small-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting. Methods A European Organisation for Research and Treatment of Cancer Lung Cancer Group (LCG)/sOM-d consensus group survey was distributed to LCG, sOM-d consensus group, and several European thoracic oncology societies’ members. Results 444 responses were analysed (radiation oncologist: 55% [n = 242], pulmonologist: 15% [n = 66], medical oncologist: 14% [n = 64]). 361 physicians (81%) aimed to cure sOM NSCLC patients and 82% (n = 362) included the possibility of radical intent treatment in their sOM-d. The maximum number of metastases considered in sOM-d varied: 12% replied 1 metastasis, 42% ≤ 3, and 17% ≥ 5 metastases. 79% (n = 353) stated that number of organs involved was important for sOM-d, and most (80%, n = 355) considered that only ≤3 involved organs (excluding primary) should be included. 317 (72%) included mediastinal lymph node involvement in the sOM-d and 22% (n = 70/317) counted mediastinal lymph node as a metastatic site. Most physicians completed sOM staging with brain magnetic resonance imaging (91%, n = 403) and positron emission tomography/computed tomography (98%, n = 437). Pathology proof of metastatic disease was a requirement to define sOM for 315 (71%) physicians. The preferred primary outcome for sOM clinical trials was overall survival (73%, n = 325). Conclusion Although consensual answers were obtained, several issues remain unresolved and will require further research to agree on a sOM-d.
- Published
- 2019
35. 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)
- Author
-
F. De Marinis, Caroline Caramella, Isabelle Monnet, Chantal Decroisette, Murielle Mauer, R. Young, Márcio José da Silva, A. Pochesci, Paolo Bironzo, Roland Schott, G. Radj, Gilles Robinet, Benjamin Besse, A. M. Dingemans, Caroline Dive, Raffaele Califano, Jessica Menis, Laurent Greillier, N. Cloarec, and Lorenzo Livi
- Subjects
business.industry ,Phases of clinical research ,Hematology ,Pembrolizumab ,Carboplatin ,chemistry.chemical_compound ,Oncology ,chemistry ,Cancer research ,Medicine ,Pd l1 expression ,Non small cell ,business ,Etoposide ,medicine.drug - Published
- 2020
36. P1.06-06 EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma
- Author
-
Paul Baas, Robin Cornelissen, A. Pochesci, Veerle Surmont, Frank Vermassen, Baktiar Hasan, Alexander P.W.M. Maat, P. Van Schil, Rabab Gaafar, and J. Van Meerbeeck
- Subjects
Pulmonary and Respiratory Medicine ,Chemotherapy ,medicine.medical_specialty ,Pleural mesothelioma ,business.industry ,medicine.medical_treatment ,Surgery ,Pleurectomy decortication ,law.invention ,Oncology ,Randomized controlled trial ,law ,medicine ,business - Published
- 2019
37. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
- Author
-
A. Prelaj, Gianluca Spitaleri, Alessia Pochesci, F. De Marinis, Antonio Passaro, G. Rossi, Chiara Catania, and E. Del Signore
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Brigatinib ,medicine.drug_class ,Pyridines ,Antineoplastic Agents ,Disease ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,0302 clinical medicine ,Organophosphorus Compounds ,Crizotinib ,hemic and lymphatic diseases ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Anaplastic lymphoma kinase ,Animals ,Humans ,Anaplastic Lymphoma Kinase ,Lung cancer ,Protein Kinase Inhibitors ,business.industry ,Cancer ,Receptor Protein-Tyrosine Kinases ,medicine.disease ,respiratory tract diseases ,Clinical trial ,030104 developmental biology ,Pyrimidines ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Mutation ,Pyrazoles ,business ,medicine.drug - Abstract
Brigatinib (AP-26113, Alunbrig) is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that is highly active in non-small cell lung cancer (NSCLC) harboring ALK translocation. Brigatinib was found to be very active against different ALK resistance mutations that mediate acquired resistance biology processes, particularly G1269A ALK C1156Y, I1171S/T, V1180L and others. Different clinical trials evaluated the activity of brigatinib in crizotinib-resistant patients, confirming high activity with durable response not only in parenchymal disease, but also in intracranial disease. Nowadays, brigatinib is under evaluation in different clinical trials exploring TKI-naive patients in the first-line setting. On the basis of its significant activity results, brigatinib received approval by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
- Published
- 2017
38. Minimally important differences for interpreting the EORTC QLQ‐C30 in patients with advanced colorectal cancer treated with chemotherapy.
- Author
-
Musoro, J. Z., Sodergren, S. C., Coens, C., Pochesci, A., Terada, M., King, M. T., Sprangers, M. A. G., Groenvold, M., Cocks, K., Velikova, G., Flechtner, H.‐H., and Bottomley, A.
- Subjects
CANCER chemotherapy ,COLORECTAL cancer ,QUALITY of life ,ABSOLUTE value ,EXPERIMENTAL design - Abstract
Aim: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30) assesses the health‐related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ‐C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ‐C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials. Method: The data were obtained from three published EORTC trials that treated CRC patients using chemotherapy. Potential anchors were selected from clinical variables based on their correlation with EORTC QLQ‐C30 scales. Anchor‐based MIDs for within‐group change and between‐group change were estimated via the mean change method and linear regression, respectively, and summarized using weighted correlation. Distribution‐based MIDs were also examined. Results: Anchor‐based MIDs were determined for deterioration in 8 of the 14 EORTC QLQ‐C30 scales and in 9 scales for improvement, and varied by scale, direction of change and anchor. MIDs for improvement (deterioration) ranged from 6 to 18 (−11 to −5) points for within‐group change and 5 to 15 (−10 to −4) for between‐group change. Summarized MIDs (in absolute values) per scale mostly ranged from 5 to 10 points. Conclusions: These findings have clinical relevance for the interpretation of treatment efficacy and the design of clinical trials by informing sample size requirements. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
39. Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
- Author
-
Chiara Catania, Gianluca Spitaleri, Alessandra Rappa, Davide Vacirca, Elena Guerini-Rocco, Filippo de Marinis, Antonio Passaro, Massimo Barberis, and Alessia Pochesci
- Subjects
0301 basic medicine ,Lung Neoplasms ,Afatinib ,Antineoplastic Agents ,Bioinformatics ,Disease-Free Survival ,03 medical and health sciences ,T790M ,0302 clinical medicine ,Gefitinib ,Carcinoma, Non-Small-Cell Lung ,medicine ,Animals ,Humans ,Osimertinib ,Rociletinib ,Lung cancer ,Pharmacology ,business.industry ,medicine.disease ,respiratory tract diseases ,ErbB Receptors ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,Erlotinib ,business ,Tyrosine kinase ,medicine.drug - Abstract
The identification of EGFR mutations and their respectively tyrosine kinase inhibitors (TKIs), changed dramatically treatment and survival of patients with EGFR-positive lung cancer. Nowadays, different EGFR TKIs as afatinib, erlotinib and gefitinib are approved worldwide for the treatment of NSCLC harbouring EGFR mutations, in particular exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations. In first-line setting, when comparing with platinum-based chemotherapy, these target drugs improves progression-free survival, response rate and quality of life. Unfortunately, the development of different mechanism of resistance, limits the long term efficacy of these agents. The most clear mechanism of resistance is the development of EGFR Thr790Met mutation. Against this new target, different third-generation EGFR-mutant-selective TKIs, such as osimertinib, rociletinib and olmutinib, showed a great activity. In this review, we summarize the scientific evidences about biology, evaluation and treatment on NSCLC with EGFR T790M mutation.
- Published
- 2016
40. Lung Tissue Injury as an Atypical Response to Nivolumab in Non–Small Cell Lung Cancer
- Author
-
Cristiano Rampinelli, Eleonora Ancona, Filippo de Marinis, Gianluca Spitaleri, Alessia Pochesci, and Antonio Passaro
- Subjects
Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Pathology ,Lung Neoplasms ,Antineoplastic Agents ,Critical Care and Intensive Care Medicine ,03 medical and health sciences ,0302 clinical medicine ,X ray computed ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Carcinoma ,Humans ,Lung cancer ,Lung ,Aged ,biology ,business.industry ,Antibodies, Monoclonal ,medicine.disease ,Nivolumab ,030104 developmental biology ,030220 oncology & carcinogenesis ,biology.protein ,Non small cell ,Antibody ,Tomography, X-Ray Computed ,business ,Lung tissue - Published
- 2017
41. Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data
- Author
-
Cristina Noberasco, Filippo de Marinis, Antonio Passaro, Alessia Pochesci, Chiara Catania, Gianluca Spitaleri, and Ester Del Signore
- Subjects
Oncology ,medicine.medical_specialty ,medicine.drug_class ,Afatinib ,medicine.medical_treatment ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,Egfr tki ,0302 clinical medicine ,Internal medicine ,medicine ,Pharmacology (medical) ,In patient ,030212 general & internal medicine ,Epidermal growth factor receptor ,General Pharmacology, Toxicology and Pharmaceutics ,Lung cancer ,Chemotherapy ,biology ,business.industry ,General Medicine ,medicine.disease ,respiratory tract diseases ,First line treatment ,030220 oncology & carcinogenesis ,biology.protein ,business ,medicine.drug - Abstract
Introduction: Epidermal growth factor receptor (EGFR) mutations are detected in about 10–15% of Caucasian and 30–40% of Asian patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In patients harbouring EGFR mutations, the treatment with different available EGFR tyrosine kinase inhibitors (TKIs) showed to be more effective and safe than platinum-based chemotherapy regimens.Areas covered: The current evidences about the role of afatinib for patients with EGFR-positive NSCLC are reviewed and discussed. We report a review based on a MEDLINE/PubMed, searched for randomized phase II or III trials evaluating afatinib in EGFR-positive NSCLC.Expert commentary: Afatinib is the third EGFR TKI approved for the treatment of NSCLC harbouring EGFR mutations, showing high efficacy in this setting of patients.
- Published
- 2016
42. RF MEMS fabrication in LTCC technology
- Author
-
Romolo Marcelli, Daniele Pochesci, Chiara Germani, Renato Croci, Ernesto Di Paola, Sergio Di Nardo, and Andrea Lucibello
- Subjects
010302 applied physics ,Microelectromechanical systems ,Fabrication ,Materials science ,business.industry ,Electrical engineering ,02 engineering and technology ,021001 nanoscience & nanotechnology ,01 natural sciences ,visual_art ,0103 physical sciences ,Electronic engineering ,Redundancy (engineering) ,visual_art.visual_art_medium ,Ceramic ,0210 nano-technology ,business ,Ohmic contact - Abstract
RF MEMS in Low-Temperature Co-fired Ceramics (LTCC) technology have been designed, manufactured and tested for potential utilization in reconfigurable space sub-systems. Specifically, single-pole-single-throw (SPST) and single-pole-double-throw (SPDT) ohmic switch configurations have been studied for wide-band applications. Advantages coming from the measured RF performances and from the integration of RF MEMS by means of the LTCC technology only, to be used also for packaging, are discussed.
- Published
- 2016
43. [Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances]
- Author
-
Alessia, Pochesci, Antonio, Passaro, Chiara, Catania, Cristina, Noberasco, Ester, Del Signore, Gianluca, Spitaleri, and Filippo, De Marinis
- Subjects
Lung Neoplasms ,Carcinoma, Non-Small-Cell Lung ,Humans ,Antineoplastic Agents ,Immunotherapy ,Disease-Free Survival - Abstract
Lung cancer represent the leading cause of cancer related-death worldwide. Although cytotoxic chemotherapy and targeted agents improved survival, the median overall survival for patients with metastatic disease remains poor. Docetaxel is still the corner stone of the second-line treatment, although associated with an unfavourable safety profile. Recent advances in the understanding of cancer immune escape system lead to the development of novel immunotherapies agent that can restore patient's immune response to cancer cells. Unlike vaccines, immune checkpoints inhibitors have shown promising results in non-small cell lung cancer patients. Especially, nivolumab and pembrolizumab, monoclonal antibodies against PD-1, provides as single agent therapy in chemotherapy refractory patients objective response rates ranging from 15%-25%, the majority of which arose quickly and were ongoing 1 year after starting treatment. Furthermore, the toxicity profile differs from that of cytotoxic chemotherapy and is much better tolerated. PD-L1 expression is a promising biomarker for selection and stratification of patients, although its prognostic and predictive role remains to be defined. Several trials are currently ongoing to define the role of immune checkpoint inhibitors in the treatment of patients with non-small cell lung cancer, their combination with cytotoxic chemotherapy or targeted agents and the efficacy and safety of double blockage of PD-1/PD-L1 and CTLA4. We report a review based on a MEDLINE/PubMed, searched for randomized phase II or III trials evaluating immune checkpoint inhibitors and NSCLC, considering the measured outcomes as progression free survival (PFS), overall survival (OS), and the overall response rate (ORR).
- Published
- 2016
44. Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
- Author
-
Alessia Pochesci, Cristina Noberasco, Gianluca Spitaleri, Filippo de Marinis, Antonio Passaro, Ester Del Signore, and Chiara Catania
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,biology ,business.industry ,Afatinib ,non-small cell lung cancer (NSCLC) ,Bioinformatics ,medicine.disease ,Research Highlight ,respiratory tract diseases ,Clinical trial ,03 medical and health sciences ,Exon ,030104 developmental biology ,0302 clinical medicine ,Gefitinib ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,biology.protein ,Erlotinib ,Epidermal growth factor receptor ,business ,Tyrosine kinase ,medicine.drug - Abstract
The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) changed dramatically the history of non-small cell lung cancer (NSCLC) harboring EGFR sensitive mutations. Several randomized prospective trials confirmed the superiority of these target agents about survival and response rate when comparing with platinum-based chemotherapy. Knowledge about EGFR mutations increased gradually during the development of target agents and different clinical trials. EGFR mutations cannot be considered all equal, but different entities should be considered in our clinical practice: exon 19 deletions, exon 21 mutation (L858R) and uncommon mutation (exon 20, exon 18 and double mutation). Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. This research highlight is an overview of data about EGFR TKIs in first-line setting, focusing on differences about exon 19 deletions and L585R mutation in patients treated with different TKIs. In addition, we report the preliminary results of the first head-to-head randomized clinical trial between two different EGFR TKIs, the LUX-Lung 7 (LL7) that compared afatinib and gefitinib showing interesting results.
- Published
- 2016
45. RF MEMS ohmic switches for matrix configurations
- Author
-
De Angelis, G.a, Lucibello, A.a, Proietti, E.a, Marcelli, R.a, Bartolucci, G.ag, Casini, F.b, Farinelli, P.b, Mannocchi, G.c, Di Nardo, S.c, Pochesci, D.c, Margesin, B.d, Giacomozzi, F.d, Vendier, O.e, Kim, T.f, Vietzorreck, and L.f
- Subjects
Simulation and characterizations of devices and circuits ,Si-based devices and IC technologies ,Microelectromechanical systems ,Modeling ,Passive components and circuits ,RF-MEMS and MOEMS ,Cantilever ,Materials science ,business.industry ,Coplanar waveguide ,Electrical engineering ,Signal Routing ,Settore ING-INF/01 - Elettronica ,ddc ,Coplanar waveguides ,Vibration ,MEMS ,Matrices ,Clos network ,Radio frequency ,Electrical and Electronic Engineering ,business ,Realization (systems) ,Ohmic contact - Abstract
Two different topologies of radio frequency micro-electro-mechanical system (RF MEMS) series ohmic switches (cantilever and clamped–clamped beams) in coplanar waveguide (CPW) configuration have been characterized by means of DC, environmental, and RF measurements. In particular, on-wafer checks have been followed by RF test after vibration, thermal shocks, and temperature cycles. The devices have been manufactured on high resistivity silicon substrates, as building blocks to be implemented in different single-pole 4-throw (SP4 T), double-pole double-throw (DPDT) configurations, and then integrated in Low Temperature Co-fired Ceramics (LTCC) technology for the realization of large-order Clos 3D networks.
- Published
- 2012
46. Computed tomography with volume rendering for the evaluation of parenchymal hyperinflation after bronchoscopic lung volume reduction☆
- Author
-
Laura Gabriella Vismara, Mohsen Ibrahim, Federico Venuta, M. Rolla, Raffaele Masciangelo, Erino A. Rendina, Ilaria Pochesci, and Antonio D'Andrilli
- Subjects
Male ,Pulmonary and Respiratory Medicine ,Spirometry ,medicine.medical_specialty ,medicine.medical_treatment ,Preoperative care ,Pneumonectomy ,Forced Expiratory Volume ,Hounsfield scale ,Parenchyma ,medicine ,Humans ,Lung volumes ,Multislice ,Prospective Studies ,Aged ,Lung ,medicine.diagnostic_test ,business.industry ,Prostheses and Implants ,General Medicine ,Middle Aged ,Dyspnea ,Treatment Outcome ,medicine.anatomical_structure ,Pulmonary Emphysema ,Female ,Surgery ,Radiology ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objective: To assess computed tomography with volume rendering (CT-VR) as a tool to evaluate parenchymal hyperinflation before and after bronchoscopic lung volume reduction (BLVR) in patients with advanced stage emphysema. Materials and methods: Between March 2006 and October 2007, we have prospectively studied pre- and postoperatively by spiral multislice CTscan and functional tests seven patients (six male, one female; age range 51—77 years, mean 64) with advanced stage heterogeneous emphysema who underwent BLVRusing the Emphasys one-way valves (Emphasys, Redwood City, CA, USA). CT parameters considered were: the volume of the ‘target’ lobe and of the entire treated lung, the diameters (antero-posterior and cranio-caudal) of the treated hemithorax and the emphysematous parenchyma rate with respect to the normal parenchyma rate of the treated lobe. Lung parenchyma has been classified as emphysematous if the density was in the 1024/900 Hounsfield units (HU) range and as normal if the density was in the 900/200 HU range. Preoperative radiological data were compared with postoperative data and plotted against spirometric data observed 1 month after treatment. Results: Overall, 24 valves have been implanted in the 7 patients. Valves have been placed in the right upper lobe in two patients, in the left upper lobe in four and in both the left upper lobe and the right lower lobe in one. Volume reduction as a proportion of the ‘target’ lobe and of the entire lung has been observed in all patients with significant differences between mean preoperative and postoperative values [p = 0.016 (target lobe); p = 0.031 (lung)]. Lobar volume reduction ranged between 1.3% and 53.7% of preoperative values. Volume reduction of the entire lung ranged between 3.1% and 16.8%. Thoracic diameters decreased in all patients after treatment with significant mean differences [p = 0.007 (antero-posterior); p = 0.004 (cranio-caudal)]. FEV1 increased in six of seven patients with significant mean differences (p = 0.025). The higher volume reduction rate has been observed in the three patients showing the better FEV1 improvement. Emphysematous lung parenchyma rate decreased postoperatively in six of seven patients with mean differences being not significant (p = 0.17).Conclusions:CT-VR is an excellent tool to confirm the efficacy of BLVR in reducingparenchymal hyperinflation. Functional advantages are proportional to the volume reduction as measured by CT-VR. # 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
- Published
- 2009
47. Abstract 2635: Baseline myeloid-derived suppressor cell and eosinophil cell counts predict clinical efficacy in patients with non-small cell lung cancer (NSCLC) treated with nivolumab in second line
- Author
-
Mancuso, Patrizia, primary, Passaro, Antonio, additional, Labanca, Valentina, additional, Gandini, Sara, additional, Spitaleri, Gianluca, additional, Guerini, Elena, additional, Barberis, Massimo, additional, Noberasco, Cristina, additional, Signore, Ester del, additional, Pochesci, Alessia, additional, Catania, Chiara, additional, Marinis, Filippo De, additional, and Bertolini, Francesco, additional
- Published
- 2017
- Full Text
- View/download PDF
48. P2.01-044 Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting
- Author
-
Passaro, Antonio, primary, Mancuso, Patrizia, additional, Labanca, Valentina, additional, Spitaleri, Gianluca, additional, Guerini-Rocco, Elena, additional, Barberis, Massimo, additional, Gandini, Sara, additional, Noberasco, Cristina, additional, Del Signore, Ester, additional, Catania, Chiara, additional, Pochesci, Alessia, additional, Bertolini, Francesco, additional, and De Marinis, Filippo, additional
- Published
- 2017
- Full Text
- View/download PDF
49. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
- Author
-
Passaro, A., primary, Prelaj, A., additional, Pochesci, A., additional, Spitaleri, G., additional, Rossi, G., additional, Del Signore, E., additional, Catania, C., additional, and de Marinis, F., additional
- Published
- 2017
- Full Text
- View/download PDF
50. Abstract 2635: Baseline myeloid-derived suppressor cell and eosinophil cell counts predict clinical efficacy in patients with non-small cell lung cancer (NSCLC) treated with nivolumab in second line
- Author
-
Elena Guerini, Patrizia Mancuso, Cristina Noberasco, Ester Del Signore, Valentina Labanca, Chiara Catania, Francesco Bertolini, Sara Gandini, Alessia Pochesci, Massimo Barberis, Antonio Passaro, Filippo de Marinis, and Gianluca Spitaleri
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Univariate analysis ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Cancer ,non-small cell lung cancer (NSCLC) ,Eosinophil ,medicine.disease ,medicine.anatomical_structure ,Internal medicine ,Immunology ,medicine ,Population study ,Peripheral blood cell ,Nivolumab ,business - Abstract
The anti-PD-1 monoclonal antibody nivolumab is clinically active in a variety of tumor types including squamous (sq) and non-squamous (non-sq) NSCLC in second-line, where randomized phase III trials have shown a survival benefit. However, no predictive/prognostic or dynamic biomarkers have been found so far to correlate with clinical benefit in patients treated with anti-PD-1 antibodies. The aim of the present study is to investigate the potential role of baseline peripheral blood cell counts in relation to survival and response rate in NSCLC patients treated with nivolumab in a second-line setting. From July to May 2016 we evaluated 45 patients with Sq (n = 10) and non-Sq (n = 35) NSCLC, previously treated with first-line platinum-based chemotherapy, who received nivolumab 3 mg/kg IV on day 1 of each 2 week treatment cycle. Clinical characteristics (T-Stage, lymph nodes involvement, M-Stage) were assessed. Total numbers of white blood cells, myeloid-derived suppressor cells (MDSCs, including both monocytic [Mo-MDSC]) and polymorphonuclear [PMN-MDSC] types), regulatory T cells (T-regs), and serum lactate dehydrogenase (LDH) were assessed. Endpoints were correlations with objective response rate (RR), progression-free survival (PFS, categorized as ≤ 3 or > 3 months) and overall survival (OS). Tumor response was assessed using RECIST criteria, version 1.1, at week 9 and every 6 weeks thereafter until disease progression. Statistical investigations were based on univariate analyses by the Wilcoxon rank test. The median PFS of the overall study population was 3 months. Data about PMN-MDSCs (identified by flow cytometry as Lin-CD15+CD14-CD11b+HLA-DRlow/-), Mo-MDSCs (Lin-CD14-CD11b+HLA-DRlow/-) and absolute eosinophil count (AEC) were available in 37/45 patients (82% of treated patients). Baseline absolute numbers of PMN-MDSCs, Mo-MDSCs and AEC were greater in patients with a good prognosis (PFS > 3 months) and a better RR. In particular, among patients with shorter PFS and lower RR, the median numbers of PMN-MDSCs, Mo-MDSCs and AEC were significantly lower than those detected in patients with longer PFS (4 vs 13 cell/µl, p=0.01; 4 vs 21 cell/µl, p=0.06; 55 vs 155 cell/µl; p=0.02, respectively). Our data suggest that a baseline blood signature characterized by low levels of PMN-MDSCs, Mo-MDSCs and AEC is associated with a poor clinical outcome (median PFS ≤ of 3 months and low RR) in 67.6% of patients treated with nivolumab. In contrast, patients with high levels of these three biomarkers showed a median PFS significantly longer than 3 months and a higher RR. The OS analysis is ongoing, and further studies have been planned to understand whether this signature has a biomarker potential also in chemotherapy-naïve, first line NSCLC patients. Citation Format: Patrizia Mancuso, Antonio Passaro, Valentina Labanca, Sara Gandini, Gianluca Spitaleri, Elena Guerini, Massimo Barberis, Cristina Noberasco, Ester del Signore, Alessia Pochesci, Chiara Catania, Filippo De Marinis, Francesco Bertolini. Baseline myeloid-derived suppressor cell and eosinophil cell counts predict clinical efficacy in patients with non-small cell lung cancer (NSCLC) treated with nivolumab in second line [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2635. doi:10.1158/1538-7445.AM2017-2635
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.